IBD is an umbrella term for chronic inflammatory bowel diseases, with a population prevalence of around 0.5%. The main types of IBD are ulcerative colitis and Crohn's disease. Unlike irritable bowel syndrome (IBS), IBD results ...
Nov 1, 2023
0
0
A cancer drug currently in the final stages of clinical trials could offer hope for the treatment of a wide range of inflammatory diseases, including gout, heart failure, cardiomyopathy, and atrial fibrillation, say scientists ...
Nov 1, 2023
0
73
The U.S. Food and Drug Administration (FDA) approved mirikizumab, on October 26, 2023, a highly effective new treatment for ulcerative colitis (UC), offering a new option to patients battling this chronic and debilitating ...
Oct 30, 2023
0
0
Use of low-dose aspirin (LDA) among pregnant women with inflammatory bowel disease (IBD) is not associated with an increased risk for disease activity, according to a study presented at the annual meeting of the American ...
Oct 27, 2023
0
0
Clostridioides difficile (C. diff) intestinal infections can cause severe, debilitating diarrhea in patients who are hospitalized or on immunosuppressive therapies. The infections can be very hard to eradicate, roaring back ...
Oct 26, 2023
0
21
Psoriasis—a chronic skin condition—is not caused or spread by spontaneous genetic mutations in the skin, new research suggests.
Oct 26, 2023
0
86
More than 10% of the population in the United States has been diagnosed with diabetes according to the Centers for Disease Control and Prevention. About 7.5% of these diabetic patients will experience cardiovascular events ...
Oct 26, 2023
0
17
For patients with inflammatory bowel disease (IBD), monitoring by intestinal ultrasound (IUS) results in reduced time to treatment change and to remission, according to a study presented at the annual meeting of the American ...
Oct 25, 2023
0
2
Certain gut-dwelling fungi flourish in severe cases of COVID-19, amplifying the excessive inflammation that drives this disease while also causing long-lasting changes in the immune system, according to a new study led by ...
Oct 23, 2023
0
86
Swiss pharmaceutical group Roche said Monday it will pay $7.1 billion to buy Telavant Holdings, a group developing new treatments for inflammatory bowel diseases.
Oct 23, 2023
0
0
